Thursday, December 3rd: 7:30 – 9:30 pm
Advances in disease stratification tools, such as molecular and imaging technologies, will help to identify more specific patient populations. This will help to unravel new mechanisms of disease in these sub-groups, and lead to better targeting of new therapies. These approaches will also be useful to identify novel endpoints that will help accelerate subsequent focused clinical trials. In this session we bring together experts to discuss whether the time has come to turn to “splitting” rather than “lumping” our patient populations.
This session is chaired by Prof. Gemma Figtree from the University of Sydney in Australia, and Dr. Joseph A Hill from UT Southwestern Medical Center, in Dallas, Texas.
The session will focus on the use of precision stratification approaches in CV trials, to improve patient phenotyping, in both CAD and heart failure trials. Additional speakers include Charalambos Antoniades (Oxford, GBR), as well as perspectives from industry: Bronwyn Kingwell (CSL, Melboure, AUS), Benoit Tyl (Servier, FRA), and regulatory: Rob Califf (Verily, Durham, USA).
Stay tuned for the post session for the moderated multi-stakeholder expert panel, when experts from all areas will try to develop a “Roadmap to CV Precision Medicine Trials.”